Journey Medical Corp
Close on Oct 19, 2026
- Market cap
- $142.14M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 12, 2026 | After market close | $18.50M | $-0.01 | $0.10 |
| Q1 FY2026 Ended Mar 31, 2026 | May 13, 2026 | After market close | $16.00M | $-0.08 | $0.02 |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 25, 2026 | After market close | $61.90M | $-0.47 | $0.10 |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | After market close | $17.60M | $-0.09 | $0.06 |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | After market close | $15.00M | $-0.16 | $-0.02 |
| Q1 FY2025 Ended Mar 31, 2025 | May 14, 2025 | After market close | $13.10M | $-0.18 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 26, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | After market close | $14.60M | $-0.12 | $0.01 |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 12, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 13, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 21, 2024 | After market close | – | – | – |
Press releases
Announcements Journey Medical filed with the SEC
Journey Medical Corporation Reports Second Quarter
Results of operations · EX-99.1 to Form 8-K
Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Corporation Secures Contract with Third Major GPO for Emrosi™
Other events · EX-99.1 to Form 8-K
Journey Medical Corporation Reports Full-Year
Results of operations · EX-99.1 to Form 8-K
Journey Medical Corporation Reports Third Quarter
Results of operations · EX-99.1 to Form 8-K
Journey Medical Corporation Reports Second Quarter
Results of operations · EX-99.1 to Form 8-K
Corporation Announces Expanded Payer Coverage for Emrosi™
Other events · EX-99.1 to Form 8-K
to Join Russell 2000 ® and Russell 3000 ® Indexes
Other events · EX-99.1 to Form 8-K
Journey Medical Corporation Reports First Quarter
Results of operations · EX-99.1 to Form 8-K
Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Journey Medical Corporation Launches Emrosi™
Other events · EX-99.1 to Form 8-K
1 | © 2025 Journey Medical Corporation. All rights reserved. EMROSI – U.S. COMMERCIAL PLAN CONFERENCE CALL February 5, 2025
Results of operations · Other events · EX-99.1 to Form 8-K
Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Journey Medical Corporation Announces U.S. FDA
Results of operations · Other events · EX-99.1 to Form 8-K
Journey Medical Corporation Reports Second
Results of operations · EX-99.1 to Form 8-K
Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Journey Medical Corporation Appoints Joseph
Executive or director change · Other events · EX-99.1 to Form 8-K
Journey Medical Corporation Reports Full-Year
Results of operations · EX-99.1 to Form 8-K
Journey Medical Corporation Secures Credit Facility
Material agreement · New financial obligation · Other events · EX-99.1 to Form 8-K
Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Journey Medical Corporation Enters into an Exclusive
Material agreement · Other events · EX-99.1 to Form 8-K
Journey Medical Corporation Reports Second Quarter
Results of operations · EX-99.1 to Form 8-K
Journey Medical Corporation Reports First Quarter
Material agreement · Results of operations · New financial obligation · EX-99.1 to Form 8-K
Journey Medical Corporation Reports Full-Year
Results of operations · EX-99.1 to Form 8-K
Corporation Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Journey Medical Corporation Reports Second Quarter
Results of operations · EX-99.1 to Form 8-K